Search | Clinical Trials Finder

Conditions: Immuno-Deficiency, COVID-19
Interventions: Evusheld; Drug
Lead sponsor: Ghady Haidar; Other
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Behavioral counseling, HIV-1 Antibody Test Kit; Other · Device
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 14
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 8 more

Conditions: X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 6 Months and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections, HIV Seronegativity
Interventions: ALVAC-HIV MN120TMG (vCP205); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2001
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: LAD1
Interventions: Ustekinumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Menlo Park, California • San Francisco, California • San Rafael, California + 15 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Interventions: Gamunex-C, 10% Injectable Solution; Drug
Lead sponsor: Grifols Biologicals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: St. Petersburg, Florida • Fort Wayne, Indiana • Westbrook, Maine + 2 more

Conditions: HIV Infections
Interventions: Potent HAART during acute or early HIV-1 infection; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Secondary Immune Deficiency
Interventions: 20% subcutaneous immunoglobulin; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Human Immunodeficiency Virus
Interventions: 3BNC117-LS, 10-1074-LS; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Immunodeficiency
Interventions: IgPro20; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Hiv, HIV/AIDS, HIV Infections, AIDS, AIDS and Infections, Aids/Hiv Problem
Interventions: N-803 and bNAbs, haNK™ Cells; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Primary Immune Deficiency Disorder
Interventions: CUTAQUIG; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Scottsdale, Arizona • Irvine, California • Santa Barbara, California + 15 more

Conditions: HIV Infection
Interventions: VRC-HIVMAB0121-00-AB; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions: Immune Globulin Intravenous (Human), 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more

Conditions: Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions: Bevacizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV/AIDS
Interventions: PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Orlando, Florida • Boston, Massachusetts • Houston, Texas

Conditions: HIV Infections
Interventions: HIV-1 C4-V3 Polyvalent Peptide Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Conditions: Common Variable Immunodeficiency
Interventions: Hizentra; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infection
Interventions: N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Search by objective public record fields.

PREP (Pre-Exposure Prophylaxis) of COVID-19

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

COVID-19 Vaccine Responses in PIDD Subjects

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

A Study of Patients With AIDS Syndrome

Observational Study of Blood Treated With Cytolin

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

A Study to Monitor Patients With Primary or Early HIV Infection

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption